Title:
METHOD FOR PREDICTING A CLINICAL RESPONSE TOWARDS AN IMMUNE CHECKPOINT INHIBITOR BASED ON PRETREATMENT THEREWITH
Document Type and Number:
WIPO Patent Application WO/2023/275407
Kind Code:
A3
Abstract:
he present invention relates to a method for predicting a clinical response in a human or animal subject suffering from or at risk of developing a neoplastic disease towards at least one given mode of treatment, said method comprising the steps of: administering to the subject at least one initial dose of an immune checkpoint inhibitor, after said initial administration, obtaining a biological sample from said subject, determining, in said sample, the expression level of at least one gene of interest selected from the group consisting of PD1, PD-L1, CTLA4, CD3, CD4, CD68, CD163 and CD8, and/or the post-treatment expression level of at least one protein of interest selected from the group consisting of LDH, GGT, and CRP, and predicting therapeutic success for follow up treatment with at least one immune checkpoint inhibitor.
Inventors:
WIRTZ RALPH MARKUS (DE)
BRÜCKL WOLFGANG (DE)
BRÜCKL NATALIE (DE)
YUAN XIAOYING (CN)
LI XINGMIN (CN)
BRÜCKL WOLFGANG (DE)
BRÜCKL NATALIE (DE)
YUAN XIAOYING (CN)
LI XINGMIN (CN)
Application Number:
PCT/EP2022/068464
Publication Date:
February 23, 2023
Filing Date:
July 04, 2022
Export Citation:
Assignee:
STRATIFYER MOLECULAR PATHOLOGY GMBH (DE)
SHUWEN BIOTECH CO LTD (CN)
SHUWEN BIOTECH CO LTD (CN)
International Classes:
C12Q1/6886
Domestic Patent References:
| WO2020172591A1 | 2020-08-27 |
Foreign References:
| US20180148790A1 | 2018-05-31 | |||
| US20190113513A1 | 2019-04-18 | |||
| US20210009697A1 | 2021-01-14 |
Other References:
YANG QIAO ET AL: "Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients", FRONTIERS IN IMMUNOLOGY, vol. 12, 16 April 2021 (2021-04-16), XP055873945, DOI: 10.3389/fimmu.2021.665133
VILAIN RICARDO E. ET AL: "Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma", CLINICAL CANCER RESEARCH, vol. 23, no. 17, 16 May 2017 (2017-05-16), US, pages 5024 - 5033, XP055873955, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-16-0698
ZAPPASODI ROBERTA ET AL: "Strategies for Predicting Response to Checkpoint Inhibitors", CURRENT HEMATOLOGIC MALIGNANCY REPORTS, SPRINGER US, NEW YORK, vol. 13, no. 5, 29 August 2018 (2018-08-29), pages 383 - 395, XP036722597, ISSN: 1558-8211, [retrieved on 20180829], DOI: 10.1007/S11899-018-0471-9
KNISPEL SARAH ET AL: "Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition", EUROPEAN JOURNAL OF CANCER, ELSEVIER, AMSTERDAM NL, vol. 148, 15 March 2021 (2021-03-15), pages 61 - 75, XP086554203, ISSN: 0959-8049, DOI: 10.1016/J.EJCA.2021.01.034
BRUECKL NATALIE F. ET AL: "Predictive value of mRNA expression and dynamic changes from immune related biomarkers in liquid biopsies before and after start of pembrolizumab in stage IV non-small cell lung cancer (NSCLC)", TRANSLATIONAL LUNG CANCER RESEARCH, vol. 10, no. 11, 11 November 2021 (2021-11-11), Hong Kong, pages 4106 - 4119, XP055981450, ISSN: 2218-6751, DOI: 10.21037/tlcr-21-587
VILAIN RICARDO E. ET AL: "Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma", CLINICAL CANCER RESEARCH, vol. 23, no. 17, 16 May 2017 (2017-05-16), US, pages 5024 - 5033, XP055873955, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-16-0698
ZAPPASODI ROBERTA ET AL: "Strategies for Predicting Response to Checkpoint Inhibitors", CURRENT HEMATOLOGIC MALIGNANCY REPORTS, SPRINGER US, NEW YORK, vol. 13, no. 5, 29 August 2018 (2018-08-29), pages 383 - 395, XP036722597, ISSN: 1558-8211, [retrieved on 20180829], DOI: 10.1007/S11899-018-0471-9
KNISPEL SARAH ET AL: "Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition", EUROPEAN JOURNAL OF CANCER, ELSEVIER, AMSTERDAM NL, vol. 148, 15 March 2021 (2021-03-15), pages 61 - 75, XP086554203, ISSN: 0959-8049, DOI: 10.1016/J.EJCA.2021.01.034
BRUECKL NATALIE F. ET AL: "Predictive value of mRNA expression and dynamic changes from immune related biomarkers in liquid biopsies before and after start of pembrolizumab in stage IV non-small cell lung cancer (NSCLC)", TRANSLATIONAL LUNG CANCER RESEARCH, vol. 10, no. 11, 11 November 2021 (2021-11-11), Hong Kong, pages 4106 - 4119, XP055981450, ISSN: 2218-6751, DOI: 10.21037/tlcr-21-587
Attorney, Agent or Firm:
MICHALSKI HÜTTERMANN & PARTNER PATENTANWÄLTE MBB et al. (DE)
Download PDF: